1374020-24-2

Upstream product

• 1374020-23-1 ethyl (RS)-2-[4-octanoylphenoxy]decanoate 
• 6974-85-2 ethyl 2-bromodecanoate 
• 2589-73-3 1-(4-hydroxyphenyl)octanone 

Downstream Products

• 1374020-28-6 (S)-2-[4-octanoylphenoxy]decanoic acid (S)-lactamide ester 
• 1374020-27-5 (R)-2-[4-octanoylphenoxy]decanoic acid (S)-lactamide ester 
• 1374020-02-6 sodium (RS)-2-[4-octanoylphenoxy]decanoate 
• 1374020-29-7 (R)-2-[4-octanoylphenoxy]decanoic acid 
• 1374020-25-3 (R)-2-[4-octanoylphenoxy]decanoic acid, sodium salt 

Relevant academic research and scientific papers

PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS

The present invention concerns the use of compounds for preventing and/or treating osteoporosis, for stimulating bone formation, for stimulating the differentiation and mineralization of osteoblasts, or for inhibiting bone resorption in a subject. These novel uses have been found for compounds represented by Formula I and pharmaceutically acceptable salts thereof. wherein: R1and R2 are independently equal to H, F or OH; A is (CH2)mCOOH, W(CH2)mCOOH, or Y-CH(COOH)-(CH2)p-CH3 when B is H; or B is (CH2)mCOOH, W(CH2)mCOOH, or Y-CH(COOH)-(CH2)p-CH3 when A is H; or A and B are covalently bonded to form a five (5), six (6), or seven (7)-membered cycloalkyl substituted with COOH; where: Y is O, S, HN or CH2; W is 0, S or NH; m is 0-2; and p is 3-7; D is CO(CH2)nCH3 or CHOH(CH2)nCH3 or 0(CH2)nCH3 where n is 2-6; and E is H or F.

PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARMACEUTICAL USES THEREOF

Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R=C(0); -OC(O)- or -CH( OH)-; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A snd B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=l-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of